What if Kevetrin turned out to not be a great cancer killer on its own? We would dip for a while and then the combo studies would start to push the sp up again, because:

Degradation of mutant p53 by
Kevetrin can chemosensitize mutant p53 cancer cells to chemotherapeutic drugs.

This drug has the potential to piggyback to just about every existing chemo regimen currently being used. It sensitizes cells to the more toxic chemo agents without adding to the overall toxic load. Even if it only has modest action as stand alone drug, it has HUGE potential as a piggyback. Longs will be seriously rewarded. This is a gamechanger even if it isn't a lead treatment.